Upsher-Smith Laboratories LLC, a subsidiary of Bora Pharmaceuticals Co Ltd (TW:6472 and OTCQX:BORAY), announced on Wednesday that it has launched its Cyclosporine Ophthalmic Emulsion 0.05%, therapeutically equivalent to the Reference Listed Drug (RLD), RESTASIS (cyclosporine ophthalmic emulsion) 0.05%.

Cyclosporine ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.

According to IQVIA, the US market for cyclosporine ophthalmic emulsion generated sales of approximately USD1.9bn in the 12 months from February 2025 to January 2026.

Bora received US Food and Drug Administration (FDA) approval of its abbreviated new drug application (ANDA) for the product in January 2026.